γ-Fe2O3 nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model

Journal of Biomedical Nanotechnology

Volumn 10, Issue 2, 2014, Pages 336-344

  Yang, Cuiping ^a,c   He, Xiangfeng ^b   Song, Lina ^d   Zhan, Xi ^e   Zhang, Yu ^d   Dou, Jun ^a   Gu, Ning ^d  

^a SOUTHEAST UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Southeast University   (China)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

ABCG2; Cancer stem cells; Multiple myeloma; Nanoparticles; Paclitaxel

Indexed keywords

ABCG2; CANCER STEM CELLS; CLONOGENIC POTENTIAL; EFFECTIVE APPROACHES; MAGNETIC NANO-PARTICLES; MULTIPLE MYELOMA; PACLITAXEL; THERAPEUTIC EFFICACY;

CELL CULTURE; DISEASES; MAMMALS; MONOCLONAL ANTIBODIES; NANOPARTICLES;

STEM CELLS;

ABCG2 MONOCLONAL ANTIBODY; AGAR; BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CD34 ANTIGEN; GAMMA IRON OXIDE NANOPARTICLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNETIC NANOPARTICLE; MONOCLONAL ANTIBODY; PACLITAXEL; SUCCIMER; SYNDECAN 1; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CASPASE; MAGNETITE NANOPARTICLE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL INVASION; CELL ISOLATION; CELL MOTILITY; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PARTICLE SIZE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CASPASES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; MAGNETITE NANOPARTICLES; MICE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NF-KAPPA B; PACLITAXEL; PARTICLE SIZE; SIGNAL TRANSDUCTION; SUCCIMER; TUMOR BURDEN;

EID: 84893204848     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1730     Document Type: Article

References (52)

1. K. Suzuki, Current therapeutic strategy for multiple myeloma. Jpn. J. Clin. Oncol. 43, 116 (2013).
2. N. Azarpira, M. Vasei, and A. Rasekhi, Plasma cell tumors with neurologic symptoms: Cytological findings. Diagn. Cytopathol. 40, 248 (2012).
3. S. Tripathy, The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a corporate hospital. J. Clin. Diagn. Res. 6, 1458 (2012).
4. D. Chaoui, B. Gallet, P. Genet, B. Mbungani, A. Al Jijakli, N. Arakelyan, L. Mesbah, and L. Sutton, High-output cardiac failure revealing primary plasma cell leukemia. Case Rep. Hematol. 2013, 504612 (2013).
5. S. Marjanović, Z. Mijusković, D. Stamatović, L. Madjaru, T. Ralić, J. Trimcev, J. Stojanović, and V. Radović, 2nd, Multiple myeloma invasion of the central nervous system. Vojnosanit Pregl. 69, 209 (2012).
6. S. Schmitt, A. D. Ho, and H. Goldschmidt, The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. Onkologie 33, 183 (2010).
7. J. Kang, A. Kumar, and C. Monteleone, Multiple myeloma presenting as recurrent sinopulmonary infections. South Med. J. 103, 260 (2010).
8. R. A. Kyle and S. V. Rajkumar, Treatment of multiple myeloma: A comprehensive review. Clin. Lymphoma Myeloma 9, 278 (2009).
9. T. S. Hawley, I. Riz, W. Yang, Y. Wakabayashi, L. Depalma, Y. T. Chang, W. Peng, J. Zhu, and R. G. Hawley, Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am. J. Hematol. 88, 265 (2013).
10. M. Cives, S. Ciavarella, F. M. Rizzo, M. De Matteo, F. Dammacco, and F. Silvestris, Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal 25, 1108 (2013).
11. J. R. Mikhael, D. Dingli, V. Roy, C. B. Reeder, F. K. Buadi, S. R. Hayman, A. Dispenzieri, R. Fonseca, T. Sher, R. A. Kyle, Y. Lin, S. J. Russell, S. Kumar, P. L. Bergsagel, S. R. Zeldenrust, N. Leung, M. T. Drake, P. Kapoor, S. M. Ansell, T. E. Witzig, J. A. Lust, R. J. Dalton, M. A. Gertz, K. Stewart, S. V. Rajkumar, A. Chanan-Khan, and M. Q. Lacy, Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo stratification of myeloma and riskadapted therapy (mSMART) consensus guidelines 2013. Mayo. Clin. Proc. 88, 360 (2013).
12. D. Cathryn, Testing ground for cancer stem cells (multiple myeloma is the ideal disease to study a controversial theory about the biology of cancer - and how to cure it). Nature 480, S43 (2011).
13. W. Matsui, C. A. Huff, Q. Wang, M. T. Malehorn, J. Barber, Y. Tanhehco, B. D. Smith, C. I. Civin, and R. J. Jones, Characterization of clonogenic multiple myeloma cells. Blood 103, 2332 (2004).
14. W. Matsui, Q. Wang, J. P. Barber, S. Brennan, B. D. Smith, I. Borrello, I. McNiece, L. Lin, R. F. Ambinder, C. Peacock, D. N. Watkins, C. A. Huff, and R. J. Jones, Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Research 68, 190 (2008).
15. J. Dou, Y. Li, F. Zhao, W. Hu, P. Wen, Q. Tang, L. Chu, Y. Wang, M. Cao, C. Jiang, and N. Gu, Identification of tumor stem like cells in mouse myeloma cell lines. Cell Mol. Biol. (Noisy-le-grand) 55, 1151 (2009).
16. V. Saini and R. H. Shoemaker, Potential for therapeutic targeting of tumor stem cells. Cancer Sci. 101, 16 (2010).
17. J. Dou, C. Jiang, J. Wang, X. Zhang, F. Zhao, W. Hu, X. He, X. Li, D. Zou, and N. Gu, Using ABCG2-molecule-expressing side population cells to identity cancer stem-like cells in a human ovarian cell line. Cell Biol. Int. 35, 227 (2011).
18. H. Zhang, J. Wang, K. Cai, L. Jiang, D. Zhou, C. Yang, J. Chen, D. Chen, and J. Dou, Down regulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. J. Cancer Res. Ther. 8, 226 (2012).
19. J. G. Turner, J. L. Gump, C. Zhang, J. M. Cook, D. Marchion, L. Hazlehurst, P. Munster, M. J. Schell, W. S. Dalton, and D. M. Sullivan, ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108, 3881 (2006).
20. J. Xu, H. Peng, and J. T. Zhang, Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr. Med. Chem. 14, 689 (2007).
21. K. J. Widder, A. E. Senyel, and G. D. Scarpelli, Magnetic microspheres: A model system of site specific drug delivery in vivo. Exp. Biol. Med. 158, 141 (1978).
22. J. Dobson, Magnetic nanoparticles for drug delivery. Drug Develop. Res. 67, 55 (2006).
23. F. Yang, Y. Li, Z. Chen, Y. Zhang, J. Wu, and N. Gu, Superparamagnetic iron oxide nanoparticle-embedded encapsulated microbubbles as dual contrast agents of magnetic resonance and ultrasound imaging. Biomaterials 30, 3882 (2009).
24. S. C. Gupta, R. Kannappan, S. Reuter, J. H. Kim, and B. B. Aggarwal, Chemosensitization of tumors by resveratrol. Ann. N. Y. Acad. Sci. 1215, 150 (2011).
25. S. S. Feng, L. Mu, K. Y. Win, and G. Huang, Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11, 413 (2004).
26. J. M. Lyons 3rd, C. T. Anthony, J. L. Thomson, and E. A. Woltering, A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer. Ann. Surg. Oncol. 15, 3407 (2008).
27. A. Jordan, P. Wust, R. Scholz, B. Tesche, H. Fähling, T. Mitrovics, T. Vogl, J. Cervós-Navarro, and R. Felix, Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic field in vitro. Int. J. Hyperthermia 12, 705 (1996).
28. 3 nanoparticles combined with magenetic fluid hyperthermia on cultured liver cancers. J. Nanosci. Nanotechnol. 5, 1185 (2000).
29. M. Wang, J. Zhang, Z. Yuan, W. Yang, Q. Wu, and H. Gu, Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles. J. Biomed. Nanotechnol. 8, 624 (2012).
30. R. R. Oliveira, F. S. Ferreira, E. R. Cintra, L. C. Branquinho, A. F. Bakuzis, and E. M. Lima, Magnetic nanoparticles and rapamycin encapsulated into polymeric nanocarriers. J. Biomed. Nanotechnol. 8, 193 (2012).
31. H. J. Lee, Y. T. C. Nguyen, M. Muthiah, H. Vu-Quang, R. Namgung, W. J. Kim, M. K. Yu, S. Jon, I. K. Lee, Y. Y. Jeong, and I. K. Park, MR traceable delivery of p53 tumor suppressor gene by PEI-functionalized superparamagnetic iron oxide nanoparticles. J. Biomed. Nanotechnol. 8, 361 (2012).
32. F. Wang, C. Ma, X. Zeng, C. Li, Y. Deng, and N. He, Chemiluminescence molecular detection of sequence-specific HBV-DNA using magnetic nanoparticles. J. Biomed. Nanotechnol. 8, 786 (2012).
33. 2 microspheres and its application for magnetic separation of nucleic acids from E. coli BL21. J. Biomed. Nanotechnol. 8, 1000 (2012).
34. S. Li, H. Liu, Y. Jia, Y. Deng, L. Zhang, Z. Lu, and N. He, A novel SNPs detection method based on gold magnetic nanoparticles array and single base extension. Theranostics 2, 967 (2012).
35. R. Qiao, C. Yang, and M. Gao, Superparamagnetic iron oxide nanoparticles: From preparations to in vivo MRI applications. J. Mater. Chem. 19, 6274 (2009).
36. 3 particles. Chem. Mater. 8, 2209 (1996).
37. S. Zhang, Z. Bian, C. Gu, Y. Zhang, S. He, N. Gu, and J. Zhang, Preparation of anti-human cardiac troponin I immunomagnetic nanoparticles and biological activity assays. Colloids Surf. B. Biointerfaces 55, 143 (2007).
38. 3/alginate/ silica microspheres for isolation of plasma DNA. Colloids Surf. A. Physicochem. Eng. Asp. 341, 33 (2009).
39. M. Ma, Y. Zhang, W. Yu, H. Y. Shen, H. Q. Zhang, and N. Gu, Preparation and characterization of magnetite nanoparticles coated by amino silane. Colloids Surf. A. Physicochem. Eng. Asp. 212, 219 (2003).
40. N. Fauconnier, J. N. Pons, J. Roger, and A. Bee, Thiolation of maghemite nanoparticles by dimercaptosuccinic acid. J. Colloid Interface Sci. 194, 427 (1997).
41. C. Yang, F. Xiong, J. Wang, J. Dou, J. Chen, D. Chen, Y. Zhang, S. Luo, and N. Gu, Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine (Lond) 3, 27 (2013).
42. + ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. B. M. C. Cell Biol. 14, 7 (2013).
43. A. Hekmat, A. A. Saboury, and A. Divsalar, The effects of silver nanoparticles and doxorubicin combination on DNA structure and its antiproliferative effect against T47D and MCF7 cell lines. J. Biomed. Nanotechnol. 8, 968 (2012).
44. T. B. Rø, T. Holien, U. M. Fagerli, H. Hov, K. Misund, A. Waage, A. Sundan, R. U. Holt, and M. Børset, HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp. Hematol. S0301-472X, 00068 (2013).
45. P. Neri, L. Ren, A. K. Azab, M. Brentnall, K. Gratton, A. C. Klimowicz, C. Lin, P. Duggan, P. Tassone, A. Mansoor, D. A. Stewart, L. H. Boise, I. M. Ghobrial, and N. J. Bahlis, Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 117, 6202 (2011).
46. X. He, J. Wang, J. Dou, F. Yu, K. Cai, X. Li, H. Zhang, and N. Gu, Antitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in mice. Exp. Ther. Med. 2, 911 (2011).
47. F. Yu, J. Wang, J. Dou, H. Yang, X. He, W. Xu, Y. Zhang, K. Hu, and N. Gu, Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine 8, 1337 (2012).
48. W. Hu, J. Wang, J. Dou, X. He, F. Zhao, C. Jiang, F. Yu, K. Hu, L. Chu, X. Li, and N. Gu, Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplant. 20, 669 (2011).
49. J. Fu, Z. Dang, Y. Deng, and G. Lu, Regulation of c-Myc and Bcl-2 induced apoptosis of human bronchial epithelial cells by zinc oxide nanoparticles. J. Biomed. Nanotechnol. 8, 669 (2012).
50. Y. Ren, K. Iimura, and T. Kato, Structure of Barium Stearate Films at the Air/Water Interface Investigated by Polarization Modulation Infrared Spectroscopy and π-A Isotherms. Langmuir 17, 2688 (2001).
51. L. Zhang, R. He, and H. C. Gu, Oleic acid coating on the monodisperse magnetite nanoparticles. Appl. Surf. Sci. 253, 2611 (2006).
52. C. Fabre, N. Mimura, K. Bobb, S. Y. Kong, G. Gorgun, D. Cirstea, Y. Hu, J. Minami, H. Ohguchi, J. Zhang, J. Meshulam, R. D. Carrasco, Y. T. Tai, P. G. Richardson, T. Hideshima, and K. C. Anderson, Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin. Cancer Res. 18, 4669 (2012).